Dexamethasone 8 mg

DRUG8 trials

Sponsors

Endeavor Health, Baylor College of Medicine, Merck Sharp & Dohme LLC, Indonesia University, Fayoum University Hospital

Conditions

Back Pain With RadiationBariatric Surgery CandidateBupivacaineDexamethasoneGastric RefluxHyperglycemia Drug InducedLower Extremities FractureLumbar Radiculopathy

Phase 1

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

RecruitingNCT02861573

Merck Sharp & Dohme LLCMetastatic Castration-Resistant Prostate Cancer

Start: 2016-11-17End: 2028-07-24Target: 1200Updated: 2026-02-17

Phase 4

Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery

CompletedNCT01545700

Endeavor HealthPostoperative Complications

Start: 2009-09-30End: 2012-11-30Updated: 2019-09-30

Dexamethasone Versus Dexmedetomidine

CompletedNCT03064633

Fayoum University HospitalPostoperative Pain

Start: 2017-03-08End: 2018-04-30Updated: 2018-06-06

Dose Dependent Steroid Injections

Not yet recruitingNCT07494136

University of MiamiBack Pain With Radiation, Lumbar Radiculopathy, Sciatica

Start: 2026-05-01End: 2027-05-01Target: 150Updated: 2026-03-27

Unknown Phase

Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg

WithdrawnNCT01641419

Baylor College of MedicinePain, Sciatic Block

Start: 2012-07-31End: 2014-12-31Updated: 2015-03-17

Comparison Between Dexamethasone and Morphine as an Adjuvant to Bupivacaine for Post-operative Analgesia

CompletedNCT03051022

Indonesia UniversityLower Extremities Fracture

Start: 2016-05-01End: 2017-03-31Updated: 2017-08-18

Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial

WithdrawnNCT05016076

YingHsuanTaiBariatric Surgery Candidate, Gastric Reflux, Hyperglycemia Drug Induced +3

Start: 2022-05-31End: 2023-08-31Updated: 2022-05-24

Effect of Adding Dexamethasone to Bupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Blocks Versus Bupivacaine Alone for Upper Limb Orthopaedic Surgery

CompletedNCT07399691

Arsi UniversityBupivacaine, Dexamethasone, Upper Limb Surgery

Start: 2024-01-01End: 2024-04-30Updated: 2026-02-10

Related Papers

Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.

2025-08-11

Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).

Journal of Clinical Oncology2025-05-281 citations

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Cell Reports Medicine2024-11-016 citations

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.

2024-06-253 citations

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

2024-03-029 citations

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Journal of Clinical Oncology2024-01-292 citations

Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.

Journal of Clinical Oncology2024-01-291 citations

Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Journal of Clinical Oncology2024-01-29

Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.

Journal of Clinical Oncology2024-01-29

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

European Urology Oncology2023-11-0710 citations

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

European Urology2022-04-0674 citations

KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

Journal of Clinical Oncology2022-02-163 citations

KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

Journal of Clinical Oncology2022-02-161 citations

KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

Journal of Clinical Oncology2022-02-161 citations

Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.

Journal of Clinical Oncology2022-02-16

351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Regular and Young Investigator Award Abstracts2021-11-014 citations

347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up

Regular and Young Investigator Award Abstracts2021-11-012 citations

419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F

Regular and Young Investigator Award Abstracts2021-11-012 citations

418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma

Regular and Young Investigator Award Abstracts2021-11-012 citations

425 Pembrolizumab + vibostolimab in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: phase 1b/2 KEYNOTE-365 cohorts G/H

Regular and Young Investigator Award Abstracts2021-11-012 citations

25 more papers not shown